Skip to main content

01.12.2012 | Research | Ausgabe 1/2012 Open Access

Health and Quality of Life Outcomes 1/2012

Beliefs about chelation among thalassemia patients

Health and Quality of Life Outcomes > Ausgabe 1/2012
Felicia L Trachtenberg, Lauren Mednick, Janet L Kwiatkowski, Ellis J Neufeld, Dru Haines, Zahra Pakbaz, Alexis A Thompson, Charles T Quinn, Robert Grady, Amy Sobota, Nancy Olivieri, Robert Horne, Robert Yamashita, Thalassemia Clinical Research Network
Wichtige Hinweise

Competing interests

The following authors declare the following financial conflicts of interest. All other authors report no conflicts of interest. Ellis Neufeld: research funding from Novartis and Ferrokin Biosciences. Charles Quinn: advisory board member of ApoPharma.

Authors’ contributions

FT performed the statistical analysis and drafted the manuscript. LM, ZP, RG, and AS helped with interpretation of data and manuscript revision. JK and EN participated in study design, acquisition of data, and manuscript revision. DH participated in acquisition of data, interpretation of data, and manuscript revision. AT, CQ, and NO participated in acquisition of data and manuscript revision. RH designed the BMQ, helped with interpretation of data, and manuscript revision. RY participated in study design, interpretation of data, and helped draft the manuscript. All authors read and approved the final manuscript.



Understanding patients’ views about medication is crucial to maximize adherence. Thalassemia is a congenital blood disorder requiring chronic blood transfusions and daily iron chelation therapy.


The Beliefs in Medicine Questionnaire (BMQ) was used to assess beliefs in chelation in thalassemia patients from North America and London in the Thalassemia Longitudinal Cohort (TLC) of the Thalassemia Clinical Research Network (TCRN). Chelation adherence was based on patient report of doses administered out of those prescribed in the last four weeks.


Of 371 patients (ages 5-58y, mean 24y), 93% were transfused and 92% receiving chelation (26% deferoxamine (DFO; a slow subcutaneous infusion via portable pump), 63% oral, 11% combination). Patients expressed high “necessity” for transfusion (96%), DFO chelation (92%) and oral chelation (89%), with lower “concern” about treatment (48%, 39%, 19% respectively). Concern about oral chelation was significantly lower than that of DFO (p<0.001). Self-reported adherence to chelation was not associated with views about necessity or concerns, but negatively correlated with perceived sensitivity to DFO (Sensitive Soma scale; r=−0.23, p=0.01) and side effects of oral chelation (r=−0.14, p=0.04). High ferritin iron levels, potentially indicating lower adherence, were found in 41% of patients reporting low necessity of oral chelation compared to 24% reporting high necessity (p=0.048). Concerns about treatment were associated with lower quality of life and more symptoms of anxiety and depression.


Despite their requirement for multimodal therapy, thalassemia patients have positive views about medicine, more so than in other disease populations. Patients may benefit from education about the tolerability of chelation and strategies to effectively cope with side effects, both of which might be beneficial in lowering body iron burden. identifier

Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

Health and Quality of Life Outcomes 1/2012 Zur Ausgabe